GSS genetic signatures limited

US launch starting

  1. 926 Posts.
    lightbulb Created with Sketch. 51
    GSS have just done a roadshow to brokers on the east coast and they rolled out the US director Mike Aicher to talk about their targeted networks in the US. He and Pat Nolan are the keys to the sales pipeline into US hospitals and path labs. WIth revenue in Australia , one year after launch here, at over $1m, you can extrapolate what that means in the US with over 5000 hospitals and a population 15x greater. Europe should see revenues in 2016 too. I think it is going to be a great year for GSS shareholders coming up!
    I heard they had good meetings with some large funds and brokers too. Do Your Own Research - there is report out by Lodge Partners and the AGM presentation is worth looking at too
    R
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
36.5¢
Change
-0.015(3.95%)
Mkt cap ! $82.90M
Open High Low Value Volume
37.0¢ 37.0¢ 36.5¢ $7.667K 20.72K

Buyers (Bids)

No. Vol. Price($)
5 16957 36.5¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 4419 1
View Market Depth
Last trade - 13.27pm 10/07/2025 (20 minute delay) ?
GSS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.